Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cidara Therapeutics Inc

CDTX
Current price
0.68 USD -0.024 USD (-3.40%)
Last closed 0.72 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 73 401 392 USD
Yield for 12 month -35.75 %
1Y
3Y
5Y
10Y
15Y
CDTX
21.11.2021 - 28.11.2021

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.6 USD

P/E ratio

Dividend Yield

Current Year

+56 541 000 USD

Last Year

+64 288 000 USD

Current Quarter

+12 718 000 USD

Last Quarter

+7 614 000 USD

Current Year

Last Year

+64 288 000 USD

Current Quarter

+12 331 000 USD

Last Quarter

+7 213 000 USD

Key Figures CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 568 000 USD
Operating Margin TTM -67.27 %
PE Ratio
Return On Assets TTM -30.38 %
PEG Ratio
Return On Equity TTM -358.92 %
Wall Street Target Price 5.6 USD
Revenue TTM 56 541 000 USD
Book Value 0.089 USD
Revenue Per Share TTM 0.68 USD
Dividend Share
Quarterly Revenue Growth YOY -68.8 %
Dividend Yield
Gross Profit TTM -11 232 000 USD
Earnings Share -0.39 USD
Diluted Eps TTM -0.39 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -54.29 %

Dividend Analytics CDTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 5.7504
Enterprise Value Revenue 0.5145
Price Sales TTM 1.2982
Enterprise Value EBITDA -0.9542
Price Book MRQ 9.1318

Financials CDTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CDTX

For 52 weeks

0.59 USD 1.48 USD
50 Day MA 0.77 USD
Shares Short Prior Month 179 466
200 Day MA 0.85 USD
Short Ratio 0.32
Shares Short 195 381
Short Percent 0.22 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics